Patent application number | Description | Published |
20090035225 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension. | 02-05-2009 |
20090036396 | RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 02-05-2009 |
20090036397 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema. | 02-05-2009 |
20100267811 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 10-21-2010 |
20110135579 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension. | 06-09-2011 |
20110190376 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema. | 08-04-2011 |
20110257248 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 10-20-2011 |
20140357696 | RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 12-04-2014 |
20150344886 | RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 12-03-2015 |
Patent application number | Description | Published |
20110257036 | Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 10-20-2011 |
20130157294 | Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 06-20-2013 |
20160084821 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CANCER SUSCEPTIBILITIES AND DEFECTIVE DNA REPAIR MECHANISMS AND TREATMENT THEREOF - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 03-24-2016 |
Patent application number | Description | Published |
20140164219 | SYSTEMS AND METHODS FOR TRANSACTION PROCESSING BASED UPON ENCODED DATA AND/OR LINKING INSTRUMENTS - The present disclosure includes a system, method, and article of manufacture for processing a transaction. The method may comprise receiving encoded data from a customer web client, receiving customer supplied data from the customer web client, processing the transaction based upon the encoded data and the customer supplied data, and transmitting a reply to the customer web client in response to the processing. Further, in various embodiments, the customer web client may scan the encoded data from a merchant web client, and/or the encoded data may encode a merchant web client identifier. Customer supplied data may include, among other things, transaction account data and/or transaction information. | 06-12-2014 |
20150294028 | Systems and Methods for Dynamic Construction of Entity Graphs - The present disclosure includes a system, method, and article of manufacture for generating an entity graph. The method may comprise determining a relationship between a first entity and a second entity based upon internal data, external data, and/or online data associated with the first entity, and generating the entity graph comprising at least two nodes and an edge connecting the at least two nodes. The method may further comprise, in various embodiments, tailoring marketing to the first entity based upon the entity graph, detecting fraud against the first entity based upon the entity graph, periodically updating the entity graph based upon new internal data and new online data, and/or adjusting the edge based upon a change in the relationship between the first entity and the second entity. | 10-15-2015 |
Patent application number | Description | Published |
20080264180 | System and method for measuring volume of ingested fluid - An audio sensor and receiver detect, discriminate and count the number of liquid swallows to determine the volume of fluid ingested. | 10-30-2008 |
20080265170 | UV detection devices and methods - A portable UV detection apparatus is disclosed. In one embodiment, the UV detection apparatus includes a UV detection device integrated with a skin type measuring device. A controller can be included in the apparatus that is in communication with the skin type measuring device and the UV detection device. The controller can provide information to the user regarding the amount of ultraviolet radiation present in the environment. In an alternative embodiment, the UV detection apparatus includes a UV detection device in conjunction with a light sensor. The light sensor can be configured to activate the UV detection device should light at a particular intensity be present in the environment. The UV detection device as described above can be configured to measure UVA radiation, UVB radiation, and/or UVC radiation. | 10-30-2008 |
20090112538 | VIRTUAL REALITY SIMULATIONS FOR HEALTH CARE CUSTOMER MANAGEMENT - Embodiments of the invention provide virtual reality tools and simulations used for improved health care customer management. The virtual reality tools may be used by a product manufacturer or seller to assist in relationship management with health care partners including identifying improved solutions for a variety of problems, strengthening infection prevention processes and systems, improving order and flow in the operating room and other care-delivery environments, identifying benefits from new products, providing techniques for evaluating new health care systems and processes, etc. | 04-30-2009 |
20090112541 | VIRTUAL REALITY TOOLS FOR DEVELOPMENT OF INFECTION CONTROL SOLUTIONS - Embodiments of the invention provide virtual reality tools used to develop improved infection control solutions. The virtual reality tools may be applied to a variety of health care environments to develop improved infection control solutions, including improved training systems for modifying human behavior regarding hand washing (or other infection control behaviors), improved systems for evaluating the effectiveness of a proposed infection control solution, and for a producer/seller of anti-microbial products to demonstrate the superiority of one product over another or the superiority of one proposed solution over another. | 04-30-2009 |
20090306934 | Instrument monitoring system - An instrument monitoring system comprises a monitoring device including a sensor for measuring an instrument and a control unit, where the control unit includes a data flow microcontroller processor; a wireless transmitter configured to receive a data signal from the monitoring device and to transmit the data signal using a wireless data transmission protocol; a wireless reader capable of receiving the data signal from the wireless transmitter; a computing device in communication with the wireless reader, where the computing device includes software configured to present the data signal as user-readable data; and a computer-readable storage medium in communication with the computing device, wherein the computer-readable storage medium is capable of storing the data. | 12-10-2009 |